Cellular and tissue components in liver, kidney and other non-target tissues

The term 'Cellular and tissue components in liver, kidney and other non-target tissues' does not describe a specific molecular target or receptor but rather refers to the broad array of biological structures where drugs may exert unintended effects, as defined in FDA safety guidelines [1]. In drug development, these tissues are primary sites for off-target toxicity and adverse drug reactions (ADRs) due to their roles in metabolism and excretion, according to NIH StatPearls [2]. The liver, containing hepatocytes and various enzymes like Cytochrome P450, is often a non-target site where metabolic activation can lead to hepatotoxicity, as detailed in the LiverTox database [3]. Similarly, the kidney's role in filtering and concentrating substances makes its cellular components, such as proximal tubule cells, vulnerable to nephrotoxicity [4]. Identifying interactions with these non-target components is a fundamental aspect of safety pharmacology and toxicology studies to ensure a drug's benefit-risk profile is acceptable [5]. Characterizing the affinity of a drug candidate for these tissues is essential for predicting its safety profile and determining the therapeutic window [6].

Other names

Off-target tissuesNon-target organsSystemic distribution sitesOff-target sites

Non-specific binding to cellular proteins, metabolic activation by cytochrome P450 enzymes to reactive intermediates, and accumulation in excretory pathways leading to oxidative stress and cellular damage.